SAN FRANCISCO, Sept. 20, 2019 InsightRX, a pioneer in precision medicine, announced today the closing of its $10 million Series A funding led by HealthX Ventures, with participation from Rock Health, OSF Healthcare, Leawood Venture Capital, Premier Inc., and earlier investor GreatPoint Ventures.
China Biologic Products Holdings Inc said on Wednesday it had received an offer from a consortium of buyers that will pay $1.93 billion in cash to buy shares that they do not already own to take the company private. Shares of the company, which develops plasma-based therapies and was listed on the Nasdaq in 2009, were up 7% after market.
China Biologic Products Holdings Inc said on Wednesday it had received a take-private deal for $4.59 billion in cash from a consortium of buyers. Shares of the company, which develops plasma-based therapies and was listed on the Nasdaq in 2009, were up 7% after market.
LAS VEGAS, Sept. 17, 2019 GB Sciences (GBLX), Inc., on Friday, September 13, 2019, filed an 8k announcing the sale of its 50% ownership stake in GB Sciences Louisiana, LLC.
RESEARCH TRIANGLE PARK, N.C., Sept. 17, 2019 Asklepios BioPharmaceutical, Inc., a fully integrated Adeno-Associated Virus gene therapy platform company focused on providing curative therapeutics for genetic disorders, has acquired the technology assets of RoverMed BioSciences.
Company aims to discover and develop psychedelic inspired medicines. TORONTO, Sept. 16, 2019 Mind Medicine, Inc., the leading neuro-pharmaceutical company focused on discovering and developing medicines based on psychedelics, has finalized the acquisition of the 18-MC drug development program, an anti-addictive molecule that was previously funded by the National Institute on Drug Abuse.
Alder Biopharmaceuticals Inc (ALDR): * ALDER BIOPHARMA - IF CO TERMINATES LUNDBECK DEAL TO ENTER INTO A SUPERIOR PROPOSAL, CO WILL BE REQUIRED TO PAY TERMINATION FEE OF $87 MILLION Source: Further company coverage:
PPF today announces the acquisition of a 19.2% stake in Autolus Therapeutics plc, a leader in next-generation T cell programming technologies. Autolus Therapeutics plc is a leader in T cell programming technologies and is developing a pipeline of next generation T cell therapies targeting both hematological cancers and solid tumors.
SAN DIEGO, Sept. 16, 2019 Amplyx Pharmaceuticals, a biotech company dedicated to developing innovative therapies for debilitating and life-threatening diseases in patients with compromised immune systems, announced today that it has executed an exclusive worldwide license agreement with Novartis under which Amplyx has acquired the rights to the Phase 2 anti-BK virus monoclonal antibody, MAU868...
BriaCell Therapeutics Corp. (BCTXF), a clinical-stage biotechnology company specializing in targeted immunotherapy for advanced breast cancer, today announces that the Company will be presenting at the 2nd Annual Next Gen Immuno-Oncology Congress, taking place September 19-20, 2019 at Hilton Garden Inn, Philadelphia Center City.
News, commentary and research reports are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.
PDF’s require Adobe® Reader® and will open in a new window.
